The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Open accessAbstract
The build-up of fluid in the peritoneal cavity-ascites-is a hallmark of ovarian cancer, the most lethal of all gynaecological malignancies. This remarkable fluid, which contains a variety of cellular and acellular components, is known to contribute to patient morbidity and mortality by facilitating metastasis and contributing to chemoresistance, but remains largely under-researched. In this review, we will critically analyse the evidence associating ascites with metastasis and chemoresistance in ovarian cancer and provide an update on research in the field. We will argue the case for ascites as a unique and accessible substrate for tracking tumour progression and for translational research that will enhance our understanding of this cancer and lead to improvements in patient outcomes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ovarian cancer cells disseminate by forming aggregates of multicellular spheroids that float in malignant ascitic fluid alongside fibroblasts, adipocytes, mesothelial, endothelial and inflammatory cells, as well as cell-free DNA, before seeding onto new microenvironments and establishing metastatic deposits.
“They disseminate by forming aggregates of multicellular spheroids that float in malignant ascitic fluid alongside fibroblasts, adipocytes, mesothelial, endothelial and inflammatory cells, as well as cell-free DNA, before “seeding” onto new microenvironments and establishing metastatic deposits (Ford et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Ford et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · see citing works
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,271 · see citing works
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,679 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · see citing works
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I. B., Trope, C. G., Amant, F. C., Kristensen, G. B., Ehlen, T., Johnson, N. P., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, Á. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,538 · see citing works
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. Q., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,413 · see citing works
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181 · see citing works
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,679 · see citing works
du Bois, A., Reuß, A., Pujade-Lauraine, É., Harter, P., Ray-Coquard, I. L., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,642 · see citing works
Pujade-Lauraine, É., Hilpert, F., Weber, B. E., Reuß, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P. O., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,623 · see citing works
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,551 · see citing works
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,472 · see citing works
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,365 · see citing works
A distinct “side population” of cells with high drug efflux capacity in human tumor cells
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Göbel, U., Goodell, M. A., & Brenner, M. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400067101 · Cited by 1,281 · see citing works
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1123 · Cited by 1,155 · see citing works
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · see citing works
Tumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 776 · see citing works
Bapat, S. A., Mali, A. M., Koppikar, C. B., & Kurrey, N. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3931 · Cited by 762 · see citing works
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.13.1853 · Cited by 715 · see citing works
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S., & Kaye, S. (2013) · Nature Reviews. Cancer · doi:10.1038/nrc3432 · Cited by 552 · see citing works
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489 · see citing works
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482 · see citing works
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983) · PubMed · Cited by 437 · see citing works
Multicellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412 · see citing works
Multicellular resistance: a paradigm for clinical resistance?
Desoize, B. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00086-x · Cited by 400 · see citing works
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Ayantunde, A. A., & Parsons, S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl499 · Cited by 391 · see citing works
Coccolini, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6979 · Cited by 326 · see citing works
Aghajanian, C. A., Goff, B. A., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 321 · see citing works
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A. L., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290 · see citing works
DISTRIBUTION OF INTRA-ABDOMINAL MALIGNANT SEEDING: DEPENDENCY ON DYNAMICS OF FLOW OF ASCITIC FLUID
Meyers, M. A. (1973) · American Journal of Roentgenology · doi:10.2214/ajr.119.1.198 · Cited by 252 · see citing works
Latifi, A., Luwor, R. B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046858 · Cited by 240 · see citing works
Grabowski, J. P., Harter, P., Heitz, F., Pujade-Lauraine, É., Reuß, A., Kristensen, G. B., Ray-Coquard, I. L., Heitz, J., Traut, A., Pfisterer, J., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.01.022 · Cited by 234 · see citing works
Giuntoli, R. L., Webb, T. J., Zoso, A., Rogers, O. C., Diaz-Montes, T. P., Bristow, R. E., & Oelke, M. (2009) · PubMed · Cited by 195 · see citing works
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
Lane, D. A., Matte, I., Rancourt, C., & Piché, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-210 · Cited by 190 · see citing works
Pereira, E. B., Camacho‐Vanegas, O., Anand, S., Sebra, R., Camacho, S. C., Garnar-Wortzel, L., Nair, N., Moshier, E. L., Wooten, M., Uzilov, A. V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145754 · Cited by 180 · see citing works
Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer
Kim, S., Kim, B., & Song, Y. S. (2016) · Cancer Science · doi:10.1111/cas.12987 · Cited by 176 · see citing works
Malignant ascites: pathophysiology and treatment
Cavazzoni, E., Bugiantella, W., Graziosi, L., Franceschini, M. S., & Donini, A. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0396-6 · Cited by 175 · see citing works
Habyan, S. A., Kalos, C., Szymborski, J., & McCaffrey, L. M. (2018) · Oncogene · doi:10.1038/s41388-018-0317-x · Cited by 158 · see citing works
Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells
Dar, S. A., Chhina, J., Mert, İ., Chitale, D. A., Buekers, T., Kaur, H., Giri, S., Munkarah, A. R., & Rattan, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-09206-0 · Cited by 156 · see citing works
Gotlieb, W. H., Amant, F. C., Advani, S. H., Goswami, C., Hirte, H. W., Provencher, D. M., Somani, N., Yamada, S., Tamby, J., & Vergote, I. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70338-2 · Cited by 151 · see citing works
Chen, M.-W., Yang, S.-T., Chien, M., Hua, K., Wu, C., Hsiao, S. M., Lin, H., Hsiao, M., Su, J.-L., & Wei, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1115 · Cited by 150 · see citing works
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer
Weidle, U. H., Birzele, F., Kollmorgen, G., & Rueger, R. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20004 · Cited by 137 · see citing works
Coelho, S. S., Silva, P. M., & Ramos, J. (1998) · PubMed · Cited by 135 · see citing works
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works
Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress
Ip, C. K. M., Li, S.-S., Tang, M. Y. H., Sy, S. K. H., Ren, Y., Shum, H. C., & Wong, A. S. T. (2016) · Scientific Reports · doi:10.1038/srep26788 · Cited by 128 · see citing works
STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
Laudisi, F., Cherubini, F., Monteleone, G., & Stolfi, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061787 · Cited by 128 · see citing works
Who are the long-term survivors of high grade serous ovarian cancer?
Hoppenot, C. M. V., Eckert, M. A., Tienda, S. M., & Lengyel, E. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.032 · Cited by 123 · see citing works
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer
Emmings, E., Mullany, S. A., Chang, Z., Landen, C. N., Linder, S. T., & Bazzaro, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010229 · Cited by 120 · see citing works
Saini, U., Naidu, S. I., ElNaggar, A. C., Bid, H. K., Wallbillich, J. J., Bixel, K. L., Bolyard, C. M., Suarez, A. A., Kaur, B., Kuppusamy, P., et al. (2016) · Oncogene · doi:10.1038/onc.2016.197 · Cited by 119 · see citing works
Peritoneal implants from ovarian tumors: CT findings.
Buy, J., Moss, A., Ghossain, M. A., Sciot, C., Malbec, L., Vadrot, D., Paniel, B., & Decroix, Y. (1988) · Radiology · doi:10.1148/radiology.169.3.3186993 · Cited by 116 · see citing works
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 111 · see citing works
Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role
Helm, C. W., & States, J. C. (2009) · Journal of Ovarian Research · doi:10.1186/1757-2215-2-2 · Cited by 106 · see citing works
Lieber, S., Reinartz, S., Raifer, H., Finkernagel, F., Dreyer, T. F., Bronger, H., Jansen, J. M., Wagner, U. A. G., Worzfeld, T., Müller, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424672 · Cited by 102 · see citing works
Husain, H., Nykin, D., Bui, N. Q., Quan, D. L., Gomez, G. G., Woodward, B. D., Venkatapathy, S., Duttagupta, R., Fung, E. T., Lippman, S. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0436 · Cited by 96 · see citing works
CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer
Pasquier, J., Gosset, M., Geyl, C., Hoarau-Véchot, J., Chevrot, A., Pocard, M. D., Mirshahi, M., Lis, R., Rafii, A., & Touboul, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0787-z · Cited by 96 · see citing works
Palliation of malignant ascites
Hodge, C., & Badgwell, B. D. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25453 · Cited by 94 · see citing works
Rafehi, S., Valdés, Y. R., Bertrand, M., McGee, J., Préfontaine, M., Sugimoto, A. K., DiMattia, G. E., & Shepherd, T. G. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0383 · Cited by 92 · see citing works
Thigpen, J. T. (2009) · Yearbook of Oncology · doi:10.1016/s1040-1741(09)79358-3 · Cited by 92 · see citing works
Kolomeyevskaya, N. V., Eng, K. H., Khan, A. N. H., Grzankowski, K. S., Singel, K. L., Moysich, K. B., & Segal, B. H. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.009 · Cited by 85 · see citing works
Herr, D., Sallmann, A., Bekes, I., Konrad, R., Holzheu, I., Kreienberg, R., & Wulff, C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.002 · Cited by 76 · see citing works
Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study
Szender, J. B., Emmons, T. R., Belliotti, S., Dickson, D., Khan, A., Morrell, K., Khan, A. N. M. N., Singel, K. L., Mayor, P. C., Moysich, K. B., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.06.008 · Cited by 75 · see citing works
Judson, P. L., Geller, M. A., Bliss, R., Boente, M. P., Downs, L. S., Argenta, P. A., & Carson, L. F. (2003) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.08.004 · Cited by 74 · see citing works
Survival of Australian women with invasive epithelial ovarian cancer: a population‐based study
Anuradha, S., Webb, P. M., Blomfield, P. I., Brand, A. H., Friedlander, M. L., Leung, Y. C., Obermair, A., Oehler, M. K., Quinn, M. A., Steer, C., et al. (2014) · The Medical Journal of Australia · doi:10.5694/mja14.00132 · Cited by 73 · see citing works
Benton, G., DeGray, G., Kleinman, H. K., George, J., & Arnaoutova, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123312 · Cited by 64 · see citing works
The Role of Cancer Stem Cells and Mechanical Forces in Ovarian Cancer Metastasis
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Repetto, T., & Mehta, G. (2019) · Cancers · doi:10.3390/cancers11071008 · Cited by 64 · see citing works
Clinical significance of ascites in epithelial ovarian cancer
Huang, H., Li, Y. J., Lan, C., Huang, Q., Feng, Y., HUANG, Y. W., & Liu, J. (2013) · Neoplasma · doi:10.4149/neo_2013_071 · Cited by 61 · see citing works
Goncharenko-Khaider, N., Matte, I., Lane, D. A., Rancourt, C., & Piché, A. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-84 · Cited by 57 · see citing works
Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer
Kim, S., Lee, M., Dhanasekaran, D. N., & Song, Y. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-5152-5 · Cited by 56 · see citing works
Berek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., Lentz, S. S., Morris, R. T., Akerley, W., Holloway, R. W., Method, M. W., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000286 · Cited by 51 · see citing works
Prospective investigation of tumor markers and risk assessment in early cancer screening
Kobayashi, T., & Kawakubo, T. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7 · Cited by 51 · see citing works
Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids.
Makhija, S. K., Taylor, D. D., Gibb, R. K., & Gerçel-Taylor, Ç. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.3.515 · Cited by 51 · see citing works
An omentum-inspired 3d peg hydrogel for identifying ecm-drivers of drug resistant ovarian cancer
Brooks, E. A., Gencoglu, M. F., Corbett, D. C., Stevens, K. R., & Peyton, S. R. (2019) · APL Bioengineering · doi:10.1063/1.5091713 · Cited by 51 · see citing works
Lane, D. A., Matte, I., Rancourt, C., & Piché, A. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-34 · Cited by 48 · see citing works
Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer
Velletri, T., Villa, C. E., Cilli, D., Barzaghi, B., Lo Riso, P., Lupia, M., Luongo, R., López-Tobón, A., De Simone, M., Bonnal, R. J. P., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-021-00878-w · Cited by 48 · see citing works
Hamilton, C. A., Miller, A., Casablanca, Y., Horowitz, N. S., Rungruang, B. J., Krivak, T. C., Richard, S. D., Rodriguez, N., Birrer, M. J., Backes, F. J., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.11.018 · Cited by 47 · see citing works
Kærn, J., Aghmesheh, M., Nesland, J. M., Danielsen, H. E., Sandstad, B., Friedlander, M. L., & Tropé, C. G. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00185.x · Cited by 46 · see citing works
Rustin, G. J. S. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr471 · Cited by 46 · see citing works
Newsted, D., Banerjee, S., Watt, K., Nersesian, S., Truesdell, P. F., Blazer, L. L., Cardarelli, L., Adams, J., Sidhu, S. S., & Craig, A. W. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1539613 · Cited by 46 · see citing works
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids
Antony, F., Deantonio, C., Cotella, D., Soluri, M. F., Tarasiuk, O., Raspagliesi, F., Adorni, F., Piazza, S., Ciani, Y., Santoro, C., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1614856 · Cited by 45 · see citing works
Matte, I., Legault, C. M., Garde‐Granger, P., Laplante, C., Bessette, P., Rancourt, C., & Piché, A. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-016-9821-y · Cited by 44 · see citing works
Krugmann, J., Schwarz, C. L., Melcher, B., Sterlacci, W., Ožalinskaitė, A., Lermann, J. H., Agaimy, A., & Vieth, M. W. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4952-9 · Cited by 44 · see citing works
Feigenberg, T., Clarke, B. A., Virtanen, C., Plotkin, A., Letarte, M., Rosen, B. P., Bernardini, M. Q., Kollara, A., Brown, T. J., & Murphy, K. J. (2014) · BioMed Research International · doi:10.1155/2014/367103 · Cited by 42 · see citing works
Malignant ascites determine the transmesothelial invasion of ovarian cancer cells
Mikuła‐Pietrasik, J., Uruski, P., Szubert, S., Szpurek, D., Sajdak, S., Tykarski, A., & Książek, K. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.09.002 · Cited by 42 · see citing works
Lee, C. K., Asher, R., Friedlander, M. L., Gebski, V., González-Martı́n, A., Lortholary, A. H., Lesoin, A., Kurzeder, C., Largillier, R., Hilpert, F., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.029 · Cited by 33 · see citing works
Zhao, H., Li, X., Chen, D., Cai, J., Fu, Y., Kang, H., Gao, J., Gao, K., & Du, N. (2015) · Medical Oncology · doi:10.1007/s12032-014-0292-1 · Cited by 30 · see citing works
Paullin, T., Powell, C. D., Menzie, C., Hill, R. G., Cheng, F., Martyniuk, C. J., & Westerheide, S. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182930 · Cited by 30 · see citing works
The Pathogenesis of Malignant Ascites
Tamsma, J. T. (2007) · Springer eBooks · doi:10.1007/978-0-387-48993-3_6 · Cited by 27 · see citing works
Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Xiao, W., Liu, Y., Cheng, G., Ji, T., Zhou, X., Zhang, T., Wan, D., Xu, S., Jin, P., Yang, X., et al. (2017) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666161221114454 · Cited by 27 · see citing works
Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk
Amankwah, E. K., Lin, H., Tyrer, J. P., Lawrenson, K., Dennis, J., Chornokur, G., Aben, K. K. H., Anton‐Culver, H., Antonenkova, N., Bruinsma, F., et al. (2015) · Genetic Epidemiology · doi:10.1002/gepi.21921 · Cited by 24 · see citing works
Jandu, N., Richardson, M., Singh, G., Hirte, H. W., & Hatton, M. W. C. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00624.x · Cited by 23 · see citing works
Kim, S., Kim, S., Kim, J., Kim, B., Kim, S. I., Kim, M. A., Kwon, S., & Song, Y. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-31097-y · Cited by 23 · see citing works
Canaz, E., Grabowski, J., Richter, R., Braicu, E. I., Chekerov, R., & Sehouli, J. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.06.014 · Cited by 23 · see citing works
Evidence for the presence of tetrodotoxin in a powder used in Haiti for zombification
Benedek, C., & Rivier, L. (1989) · Toxicon · doi:10.1016/0041-0101(89)90210-9 · Cited by 21 · see citing works
Ohsuga, T., Yamaguchi, K. D., Kido, A., Murakami, R., Abiko, K., Hamanishi, J., Kondoh, E., Baba, T., Konishi, I., & Matsumura, N. (2017) · BMC Cancer · doi:10.1186/s12885-017-3573-1 · Cited by 21 · see citing works
Ito, T., Hanafusa, N., Iwase, S., Noiri, E., Nangaku, M., Nakagawa, K., & Miyagawa, K. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12863 · Cited by 20 · see citing works
Matte, I., Garde‐Granger, P., Bessette, P., & Piché, A. (2019) · Europe PMC (PubMed Central) · Cited by 20 · see citing works
Early detection: a long road ahead
(2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0021-8 · Cited by 19 · see citing works
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
Chelariu-Raicu, A., Coleman, R. L., & Sood, A. K. (2019) · PubMed · Cited by 17 · see citing works
Piché, A. (2018) · World Journal of Clinical Oncology · doi:10.5306/wjco.v9.i8.167 · Cited by 13 · see citing works
Wang, Y., Yang, B., Zhao, J., Yu, X., Liu, X., Zhang, L., Zhang, Y., Li, X., & Zhai, Z. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9814 · Cited by 13 · see citing works
Wei, G., Chen, H., Nie, F., Ma, X., & Jiang, H. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150914114649 · Cited by 12 · see citing works
Characterizing the Cancer Genome in BloodPreprint
Dawson, S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026880 · Cited by 12 · see citing works
Yunusova, N. V., Виллерт, А. Б., Спирина, Л. В., Frolova, A. E., Коломиец, Л. А., & Кондакова, И. В. (2016) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2016.17.12.5315 · Cited by 10 · see citing works
Tóth, L., Nagy, B. M., Méhes, G., Laszlo, E., Molnár, P., Póka, R., & Hernádi, Z. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.05.014 · Cited by 10 · see citing works
Berek, J. S., Edwards, R. P., Parker, L. M., DeMars, L. R., Herzog, T. J., Lentz, S. S., Morris, R. T., Akerley, W., Holloway, R. W., Method, M. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.5048 · Cited by 9 · see citing works
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
Rustin, G. J. S., & Hall, M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw253 · Cited by 8 · see citing works
Lai, I., Daniel, M. N., Rosen, B. P., May, T., Massey, C., & Feigenberg, T. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000310 · Cited by 8 · see citing works
Single cell derived organoids capture the self-renewing subpopulations of metastatic ovarian cancerPreprint
Velletri, T., Villa, C. E., Lupia, M., Riso, P. L., Luongo, R., Tobon, A., Simone, M. C. D., Bonnal, R. J. P., Minucci, S., Piccolo, S., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/484121 · Cited by 6 · see citing works
Zaman, G. J. R., den Ouden, J. E., Dylus, J., van Doornmalen, A. M., Buijsman, R. C., Eijkelenboom, A., Massuger, L. F. A. G., & van Altena, A. M. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-2221 · Cited by 2 · see citing works
Kwon, M., & Libutti, S. K. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.05.23 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., et al. (2021) · Cancers · doi:10.3390/cancers13174318 · Cited by 154 · see citing works
Luo, Y., Xia, Y., Liu, D., Li, X., Li, H., Liu, J., Zhou, D., Dong, Y. J., Li, X., Qian, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.013 · Cited by 115 · see citing works
Tumor microenvironment in ovarian cancer peritoneal metastasis
Mei, S., Chen, X., Wang, K., & Chen, Y. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02854-5 · Cited by 112 · see citing works
Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers
Wenk, D., Zuo, C., Kislinger, T., & Sepiashvili, L. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09452-1 · Cited by 104 · see citing works
TGFβ signaling networks in ovarian cancer progression and plasticity
Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 76 · see citing works
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works
Wang, W., Jo, H., Park, S., Kim, H., Kim, S. I., Han, Y., Lee, J., Seol, A., Kim, J., Lee, M., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215735 · Cited by 67 · see citing works
Biology-driven therapy advances in high-grade serous ovarian cancer
Wang, Y., Duval, A. J., Adli, M., & Matei, D. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174013 · Cited by 70 · see citing works
Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells
Segal, B. H., Giridharan, T., Suzuki, S., Khan, A. N. H., Zsíros, E., Emmons, T. R., Yaffe, M. B., Gankema, A. A. F., Hoogeboom, M., Goetschalckx, I., et al. (2022) · Immunological Reviews · doi:10.1111/imr.13178 · Cited by 65 · see citing works
Carvalho, R. F., do Canto, L. M., Abildgaard, C., Aagaard, M. M., Tronhjem, M. S., Waldstrøm, M., Jensen, L. H., Steffensen, K. D., & Rogatto, S. R. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00991-4 · Cited by 53 · see citing works
Yokoi, A., Yoshida, K., Koga, H., Kitagawa, M., Nagao, Y., Iida, M., Kawaguchi, S., Zhang, M., Nakayama, J., Yamamoto, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42593-9 · Cited by 50 · see citing works
Frisbie, L. G., Pressimone, C. A., Dyer, E., Baruwal, R., Garcia, G. L., Croix, C. M. S., Watkins, S. C., Calderone, M., Gorecki, G., Javed, Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114551 · Cited by 50 · see citing works
Tarannum, M., Dinh, K., Vergara, J. A., Birch, G. C., Abdulhamid, Y. Z., Kaplan, I. E., Ay, O., Maia, A., Beaver, O., Sheffer, M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn0881 · Cited by 48 · see citing works
Rakina, M. A., Казакова, А., Виллерт, А. Б., Коломиец, Л. А., & Larionova, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116215 · Cited by 47 · see citing works
Tomás-Pérez, S., Oto, J., Aghababyan, C., Herranz, R., Cuadros-Lozano, A., González-Cantó, E., Cormack, B. A. M., Arrés, J., Castaño, M., Cana, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111344 · Cited by 45 · see citing works
Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective
Qian, L., Sun, R., Xue, Z., & Guo, T. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100578 · Cited by 45 · see citing works
Castaño, M., Tomás-Pérez, S., González-Cantó, E., Aghababyan, C., Mascarós-Martínez, A., Santonja, N., Herreros‐Pomares, A., Oto, J., Medina, P., Götte, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065995 · Cited by 42 · see citing works
The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models
Tadić, V., Zhang, W., & Brozović, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189052 · Cited by 42 · see citing works
Capellero, S., Erriquez, J., Battistini, C., Porporato, R., Scotto, G., Borella, F., Renzo, M. F. D., Valabrega, G., & Olivero, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020833 · Cited by 42 · see citing works
Casagrande, N., Borghese, C., Agostini, F., Durante, C., Mazzucato, M., Colombatti, A., & Aldinucci, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063019 · Cited by 41 · see citing works
Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer
Werner, B., Yuwono, N. L., Duggan, J., Liu, D., David, C., Srirangan, S., Provan, P. J., DeFazio, A., Arora, V., Farrell, R., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.06.028 · Cited by 40 · see citing works
Ye, Z., Xu, S., Shi, Y. P., Cheng, X., Zhang, Y., Roy, S., Namjoshi, S., Longo, M. A., Link, T. M., Schlacher, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46283-y · Cited by 39 · see citing works
Circulating Proteins as Diagnostic Markers in Gastric Cancer
Repetto, O., Vettori, R., Steffan, A., Cannizzaro, R., & Re, V. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316931 · Cited by 38 · see citing works
Uno, K., Iyoshi, S., Yoshihara, M., Kitami, K., Mogi, K., Fujimoto, H., Sugiyama, M., Koya, Y., Yamakita, Y., Nawa, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084383 · Cited by 36 · see citing works
Qi, L., Chen, D., Li, C., Li, J., Wang, J., Zhang, C., Li, X., Qiao, G., Wu, H., Zhang, X., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.753948 · Cited by 33 · see citing works
Kim, S., Han, Y., Kim, S. I., Lee, J., Jo, H., Wang, W., Cho, U., Park, W., Rando, T. A., Dhanasekaran, D. N., et al. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23289 · Cited by 32 · see citing works
Rickard, B. P., Tan, X. M., Fenton, S. E., & Rizvi, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095176 · Cited by 34 · see citing works
Bortot, B., Apollonio, M., Rampazzo, E., Valle, F., Brucale, M., Ridolfi, A., Ura, B., Addobbati, R., Lorenzo, G. D., Romano, F., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13110 · Cited by 33 · see citing works
Kotrbova, A. V., Gömöryová, K., Mikulová, A., Plešingerová, H., Sladeček, S., Kravec, M., Hrachovinová, Š., Potěšil, D., Dunsmore, G., Blériot, C., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12420 · Cited by 31 · see citing works
Li, Y., Hu, Y., Yang, L., Liu, J., Cui, C., Yang, M., Zou, D., Zhou, L., Zhou, Q., Ge, W., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114350 · Cited by 31 · see citing works
Wang, H., Yung, M. M. H., Yang, X., Chen, F., Chan, W., Siu, M. K. Y., Long, R., Jia, S., Liang, Y., Xu, D., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00558-8 · Cited by 31 · see citing works
Luo, H., She, X., Zhang, Y., Xie, B., Zhang, S., Li, Q., Zhou, Y., Guo, S., Zhang, S., Jiang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202411314 · Cited by 31 · see citing works
Multicellular ovarian cancer spheroids: novel 3D model to mimic tumour complexity
Flörkemeier, I., Antons, L. K., Weimer, J. P., Hedemann, N., Rogmans, C., Krüger, S., Scherließ, R., Dempfle, A., Arnold, N., Maass, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73680-6 · Cited by 30 · see citing works
Han, L., Xu, S., Zhou, D., Chen, R., Ding, Y., Zhang, M., Bao, M., He, B., & Li, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1401648 · Cited by 29 · see citing works
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells
Tonetti, C. R., de Souza-Araújo, C. N., Yoshida, A., da Silva, R. F., Alves, P. C. M., Mazzola, T. N., Derchain, S., Fernandes, L. G. R., & Guimarães, F. (2021) · Cells · doi:10.3390/cells10071702 · Cited by 29 · see citing works
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Sandoval, T. A., Salvagno, C., Chae, C.-S., Awasthi, D., Giovanelli, P., Falco, M. M., Hwang, S., Terán-Cabanillas, E., Suominen, L., Yamazaki, T., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1451 · Cited by 29 · see citing works
Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
Hilliard, T. S., Kowalski, B., Iwamoto, K., Agadi, E., Liu, Y., Yang, J., Asem, M., Klymenko, Y., Johnson, J. J., Shi, Z., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212443 · Cited by 27 · see citing works
Targeting Aquaporins in Novel Therapies for Male and Female Breast and Reproductive Cancers
Khan, S., Ricciardelli, C., & Yool, A. J. (2021) · Cells · doi:10.3390/cells10020215 · Cited by 25 · see citing works
Teng, K., Ford, M. J., Harwalkar, K., Li, Y., Pacis, A., Farnell, D., Yamanaka, N., Wang, Y.-C., Badescu, D., Nu, T. N. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1518 · Cited by 25 · see citing works
Zhao, Z., Xu, H., Wei, Y., Sun, L., & Song, Y. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166594 · Cited by 25 · see citing works
Zhang, J., Yin, Z., Liang, Z., Bai, Y., Zhang, T., Yang, J., Li, X., & Xue, L. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0136 · Cited by 24 · see citing works
Monavarian, M., Elhaw, A. T., Tang, P. W., Javed, Z., Shonibare, Z., Scalise, C. B., Arend, R. C., Jolly, M. K., Sewell-Loftin, M. K., Hempel, N., et al. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.004 · Cited by 24 · see citing works
Aquino-Acevedo, A. N., Knochenhauer, H. E., Castillo-Ocampo, Y., Ortiz-León, M., Rivera-López, Y. A., Morales-López, C., Cruz-Robles, M. E., Hernández-Cordero, E. R., Russell, S., Whitaker, R. S., et al. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100558 · Cited by 25 · see citing works
Hugendieck, G., Lettau, M., Andreas, S., Neumann, S., Reinhardt, N., Arnold, P., Theilig, F., Bastian, L., Rogmans, C., Weimer, J. P., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12338 · Cited by 23 · see citing works
Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology
Werner, B., Warton, K., & Ford, C. E. (2022) · Cancers · doi:10.3390/cancers14051309 · Cited by 22 · see citing works
Sphingolipids as multifaceted mediators in ovarian cancer
Pitman, M. R., Oehler, M. K., & Pitson, S. M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.109949 · Cited by 21 · see citing works
Casagrande, N., Borghese, C., Gabbatore, L., Morbiato, L., Zotti, M. D., & Aldinucci, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168362 · Cited by 21 · see citing works
Metabolic Reprogramming of Ovarian Cancer Spheroids during Adhesion
Compton, S. L. E., Grieco, J. P., Gollamudi, B., Bae, E., Mullekom, J. H. V., & Schmelz, E. M. (2022) · Cancers · doi:10.3390/cancers14061399 · Cited by 20 · see citing works
Miyazaki, M., Nakabo, A., Nagano, Y., Nagamura, Y., Yanagihara, K., Ohki, R., Nakamura, Y., Fukami, K., Kawamoto, J., Umayahara, K., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215983 · Cited by 20 · see citing works
Nunes, M., Duarte, D., Vale, N., & Ricardo, S. A. V. (2022) · Cancers · doi:10.3390/cancers14184357 · Cited by 19 · see citing works
In Vitro Models of Ovarian Cancer: Bridging the Gap between Pathophysiology and Mechanistic Models
Lopez, E., Kamboj, S., Chen, C., Wang, Z., Kellouche, S., Leroy‐Dudal, J., Carreiras, F., Lambert, A., & Aimé, C. (2023) · Biomolecules · doi:10.3390/biom13010103 · Cited by 21 · see citing works
Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells
Carmi, Y. K., Agbarya, A., Khamaisi, H., Farah, R. E., Shechtman, Y., Korobochka, R., Gopas, J., & Mahajna, J. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101939 · Cited by 19 · see citing works
Li, C., Men, C., Yang, W., Chen, R., Zhu, J., & Cheng, Z. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12652 · Cited by 18 · see citing works
Yamaguchi, H., & Miyazaki, M. (2025) · Cancer Science · doi:10.1111/cas.70021 · Cited by 18 · see citing works
Athira, M., Lekshmi, G. S., Rajeev, M. R., & Anirudhan, T. S. (2025) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2025.116239 · Cited by 18 · see citing works
Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets
Qiu, Y., Chen, Y., Agbede, O., Eshaghi, E., & Peng, C. (2022) · Cancers · doi:10.3390/cancers14225711 · Cited by 18 · see citing works
Silva, R., Glennon, K., Metoudi, M., Moran, B., Salta, S., Slattery, K., Treacy, A. D., Martin, T., Shaw, J., Doran, P., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34496 · Cited by 18 · see citing works
Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer
Chen, M., Li, Y., Wu, Y., Xie, S., Ma, J., Yue, J., Lv, R., Tian, Z., Fang, F., & Xiao, W. (2021) · Cancers · doi:10.3390/cancers13225866 · Cited by 18 · see citing works
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance
Grillo, E., Romani, C., Ettorre, V. M., Santin, A. D., & Mitola, S. M. F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189374 · Cited by 17 · see citing works
Malignant ascites in ovarian cancer: New advances and translational opportunities
Boo, K. H., Lee, G., & Song, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102568 · Cited by 17 · see citing works
Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC
Arend, R. C., Scalise, C. B., Gordon, E. R., Davis, A. M., Foxall, M. E., Johnston, B. E., Crossman, D. K., & Cooper, S. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2984 · Cited by 17 · see citing works
Limitations and potential of immunotherapy in ovarian cancer
Kumar, S., Acharya, S., Karthikeyan, M., Biswas, P., & Kumari, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292166 · Cited by 17 · see citing works
A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells
Śliwa, A., Szczerba, A., Pięta, P., Białas, P., Lorek, J., Nowak‐Markwitz, E., & Jankowska, A. (2024) · Cancers · doi:10.3390/cancers16040783 · Cited by 17 · see citing works
Zhang, J., He, T., Yin, Z., Shang, C., Xue, L., & Guo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.864021 · Cited by 17 · see citing works
Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis
Hendrikson, J., Liu, Y., Ng, W. H., Lee, J. Y., Lim, A. H., Loh, J. W., Ng, C. C. Y., Ong, W. S., Tan, J. W., Tan, Q. X., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100526 · Cited by 16 · see citing works
Friend and foe: the regulation network of ascites components in ovarian cancer progression
Geng, Z., Pan, X., Xu, J., & Jia, X. (2022) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-022-00698-8 · Cited by 15 · see citing works
Gendrau‐Sanclemente, N., Figueras, A., Gracova, K., Lahiguera, Á., Alsina‐Sanchís, E., Marín‐Jiménez, J. A., Vidal, A., Matías‐Guiu, X., Fernández-González, S., Barahona, M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13556 · Cited by 15 · see citing works
Zheng, C., Niu, G., Tan, H., Huang, X., Lu, J., Mai, Q., Yu., T. S., Zhang, C., Chen, S., Wei, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58525-8 · Cited by 15 · see citing works
Thorel, L., Dolivet, É., Morice, P., Florent, R., Divoux, J., Perréard, M., Lecouflet, L., Desmartin, G., Alagama, C. M., Giffard, F., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03537-x · Cited by 14 · see citing works
Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics
Dogra, S., Adhikari, L., Benbrook, D. M., Bohn, J. A., Burgett, A. W. G., Chandra, V., Dockery, L., Singh, A., McNally, L. R., Rai, R., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02438-z · Cited by 14 · see citing works
Nasioudis, D., Byrne, M. E., Ko, E. M., Haggerty, A. F., Cory, L. A., Giuntoli, R. L., Kim, S. H., & Latif, N. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002978 · Cited by 14 · see citing works
Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins
Almeida-Nunes, D. L., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010323 · Cited by 14 · see citing works
Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization
Chung, D. C., Garcia-Batres, C. R., Millar, D. G., Wong, S. W., Elford, A. R., Mathews, J. A., Wang, B. X., Nguyen, L. T., Shaw, P. A., Clarke, B. A., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300834 · Cited by 14 · see citing works
Thorel, L., Divoux, J., Lequesne, J., Babin, G., Morice, P., Florent, R., Desmartin, G., Lecouflet, L., Alagama, C. M., Leconte, A., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12429-w · Cited by 14 · see citing works
Cardiac Atrophy, Dysfunction, and Metabolic Impairments
Ogilvie, L. M., Delfinis, L. J., Coyle‐Asbil, B., Vudatha, V., Alshamali, R., Garlisi, B., Pereira, M., Matuszewska, K., Garibotti, M. C., Gandhi, S., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.06.008 · Cited by 14 · see citing works
Shi, G., Shi, P., Yu, Y., Xu, J. X., Ma, J., Zhang, Y., Dong, Z., Shen, L., Dai, L., Cheng, L., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.008 · Cited by 14 · see citing works
Cortesi, M., Liu, D., Yee, C., Marsh, D. J., & Ford, C. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-42486-3 · Cited by 14 · see citing works
Progress in the treatment of malignant ascites
Wang, Y., Sun, Y., Li, X., Yu, X., Zhang, K., Liu, J., Tian, Q., Zhang, H., Du, X., & Wang, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104237 · Cited by 14 · see citing works
A nomogram model based on clinical markers for predicting malignancy of ovarian tumors
Gao, B., Zhao, X., Gu, P., Sun, D., Liu, X., Li, W., Zhang, A., Peng, E., & Xu, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.963559 · Cited by 13 · see citing works
Nelson, L., Barnes, B. M., Tighe, A., Littler, S., Coulson‐Gilmer, C., Golder, A., Desai, S. N., Morgan, R. D., McGrail, J. C., & Taylor, S. S. (2023) · Chromosome Research · doi:10.1007/s10577-023-09731-x · Cited by 13 · see citing works
The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers
Henderson, E. C., Huynh, G. T., Wilson, K., Plebanski, M., & Corrie, S. R. (2021) · Biomedicines · doi:10.3390/biomedicines9111554 · Cited by 13 · see citing works
Nunes, M., Duarte, D., Vale, N., & Ricardo, S. A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010097 · Cited by 12 · see citing works
Li, J., Faruque, H. A., Li, S., Sima, M., Sborov, D. W., Hu‐Lieskovan, S., Werner, T. L., Kopeček, J., & Yang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113682 · Cited by 12 · see citing works
Yu, J., Che, L., Zhu, A., Xu, L., & Huang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.833273 · Cited by 12 · see citing works
Pampeno, C., Opp, S., Hurtado, A. M., & Meruelo, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052925 · Cited by 11 · see citing works
Romaniuk-Drapała, A., Skupin-Mrugalska, P., Garbuzenko, O. B., Hatefi, A., & Minko, T. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03469-0 · Cited by 11 · see citing works
Ovarian cancer extracellular vesicle biomarkers
Jamali, Z., Razipour, M., Zargar, M., Ghasemnejad‐Berenji, H., & Akrami, S. M. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.120011 · Cited by 11 · see citing works
Advanced Therapeutic Approaches for Metastatic Ovarian Cancer
Choe, S., Jeon, M., & Yoon, H. (2025) · Cancers · doi:10.3390/cancers17050788 · Cited by 11 · see citing works
Lupia, M., Melocchi, V., Bizzaro, F., Riso, P. L., Dama, E., Baronio, M., Ranghiero, A., Barberis, M. C. P., Bernard, L., Bertalot, G., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33983 · Cited by 11 · see citing works
Li, Y., Wang, W., Wang, D., Zhang, L., Wang, X., He, J., Cao, L., Li, K., & Xie, H. (2022) · Genes · doi:10.3390/genes13122276 · Cited by 11 · see citing works
Mulchandani, V., Banerjee, A., Vadlamannati, A. V., Kumar, S., & Sarma, J. D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114296 · Cited by 11 · see citing works
A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites
Chen, W., Liu, H., Huang, X., Qian, L., Chen, L., Yong-gang, Z., Liu, Y., Liu, Y., Wang, Y., Zhang, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107712 · Cited by 12 · see citing works
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression
Almeida-Nunes, D. L., Nunes, M., Osório, H., Ferreira, V., Lobo, C., Monteiro, P., Abreu, M. H., Bartosch, C., Silvestre, R., Dinis‐Oliveira, R. J., et al. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101755 · Cited by 10 · see citing works
Deng, S., Kim, W., Cheng, K., Yang, Q., Singh, Y., Bae, G., Bézière, N., Mager, L. F., Kommoss, S., Sprengel, J., et al. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00391-5 · Cited by 10 · see citing works
Insights into the tumor-stromal-immune cell metabolism cross talk in ovarian cancer
Tang, P. W., Frisbie, L. G., Hempel, N., & Coffman, L. G. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00588.2022 · Cited by 10 · see citing works
Luo, N., Sulaiman, Z., Wang, C., Ding, J., Chen, Y., Liu, B., Cheng, Z., & Liu, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03404-9 · Cited by 10 · see citing works
Chen, K., Zhai, Y., Wang, Y., Xu, Z., Chen, X., Zhang, Y., Zhou, Z., Zheng, X., & Lin, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117110 · Cited by 9 · see citing works
Zhou, S., Xu, J., Gao, X.-Q., Zhang, R., Cheng, F.-F., Yao, W.-F., Zhang, Y., Geng, T., & Zhang, L. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155895 · Cited by 9 · see citing works
Liu, Y., Xiao, H., Zeng, H., & Xiang, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5705 · Cited by 10 · see citing works
Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma
Bienes, K. M., Yokoi, A., Kitagawa, M., Kajiyama, H., Thaysen‐Andersen, M., & Kawahara, R. (2025) · BBA Advances · doi:10.1016/j.bbadva.2025.100140 · Cited by 9 · see citing works
- Authors
- Ford, C. E., Werner, B., Hacker, N. F., & Warton, K.
- Affiliations
- UNSW Sydney (AU)
- Corresponding author
- Ford, Caroline Elizabeth
- Venue
- British Journal of Cancer
- Published
- 2020-05-08
- Volume
- 123
- Issue
- 1
- Pages
- 9-16
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC7341795
- OpenAlex
- W3022087601
- Cited by
- 261
- References
- 110
- Citations by year
- 2026: 44 · 2025: 51 · 2024: 60 · 2023: 46 · 2022: 42 · 2021: 18
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Translational Cancer Research Network
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- ascites, ovarian cancer, peritoneal carcinomatosis, chemoresistance, translational research
- MeSH terms
- Ascites, Female, Humans, Ovarian Neoplasms, Ovary, Biomarkers, Tumor, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
